Marshall Wace LLP Takes Position in Astrana Health, Inc. (NASDAQ:ASTH)

Marshall Wace LLP purchased a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 89,472 shares of the company's stock, valued at approximately $2,821,000. Marshall Wace LLP owned about 0.16% of Astrana Health as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ASTH. Handelsbanken Fonder AB grew its stake in shares of Astrana Health by 4.7% in the fourth quarter. Handelsbanken Fonder AB now owns 8,900 shares of the company's stock worth $281,000 after acquiring an additional 400 shares during the last quarter. Swiss National Bank grew its position in Astrana Health by 1.1% in the 4th quarter. Swiss National Bank now owns 88,444 shares of the company's stock worth $2,789,000 after purchasing an additional 1,000 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Astrana Health by 19.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 7,124 shares of the company's stock worth $225,000 after purchasing an additional 1,184 shares during the period. Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Astrana Health during the fourth quarter valued at about $40,000. Finally, Pictet Asset Management Holding SA lifted its stake in shares of Astrana Health by 21.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 7,075 shares of the company's stock valued at $223,000 after buying an additional 1,273 shares during the period. 52.77% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on ASTH. Bank of America reduced their price objective on Astrana Health from $55.00 to $49.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Truist Financial reduced their price objective on shares of Astrana Health from $50.00 to $46.00 and set a "buy" rating for the company in a report on Tuesday, March 18th. Barclays began coverage on shares of Astrana Health in a research note on Tuesday, April 1st. They issued an "equal weight" rating and a $36.00 target price on the stock. Stifel Nicolaus cut their price target on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating for the company in a research note on Thursday, February 20th. Finally, Robert W. Baird decreased their price objective on Astrana Health from $86.00 to $50.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $53.29.

Astrana Health Price Performance

Shares of Astrana Health stock traded up $0.37 during trading on Friday, reaching $31.81. The company's stock had a trading volume of 34,337 shares, compared to its average volume of 277,870. Astrana Health, Inc. has a one year low of $23.12 and a one year high of $63.20. The stock has a 50-day moving average price of $30.73 and a two-hundred day moving average price of $37.58. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $1.59 billion, a P/E ratio of 24.44, a price-to-earnings-growth ratio of 1.37 and a beta of 1.04.

Astrana Health (NASDAQ:ASTH - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The company had revenue of $665.21 million for the quarter, compared to the consensus estimate of $617.24 million. As a group, sell-side analysts anticipate that Astrana Health, Inc. will post 1.15 EPS for the current fiscal year.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.